Genenta Imaging Partnership with IAG Optimizes Phase I/IIa Study of Temferon™ in Glioblastoma Posted on February 2, 2021February 2, 2021 by genenta
Genenta to take part in gene therapy panel and two virtual investor events in January 2021 Posted on January 5, 2021January 7, 2021 by genenta
Genenta to appoint Stephen Squinto, experienced biotech executive and investor, as Chairman Posted on November 23, 2020 by genenta
Genenta’s TemferonTM: Evidence of Controlled and Targeted Interferon Expression in Preliminary Phase I/II Clinical Data in Glioblastoma Multiforme Posted on November 16, 2020 by genenta
Genenta to present preliminary Phase I/II clinical data on TemferonTM in glioblastoma multiforme at Chardan’s 4th Annual Genetic Medicines Conference Posted on September 30, 2020October 15, 2020 by genenta
Genenta presents company’s pipeline and the preliminary clinical data from Phase I/II in patients affected with glioblastoma multiforme at the Advanced Therapies Congress & Expo 2020 Posted on September 8, 2020October 15, 2020 by genenta
Genenta to present at the LifeSci Partners Summer Symposium Posted on July 30, 2020November 30, 2020 by genenta
Genenta presents the company overview at the Access China Forum 2020 Posted on July 30, 2020October 15, 2020 by genenta
Genenta presents at ASGCT preliminary pre-clinical and clinical data from TemferonTM Phase 1/2 study in patients with glioblastoma multiforme Posted on May 15, 2020October 15, 2020 by genenta
Genenta presents preliminary pre-clinical and clinical data from a Phase 1/2 study in patients with glioblastoma multiforme at American Society of Gene & Cell Therapy Posted on May 4, 2020October 15, 2020 by genenta